Limited Humoral and Specific T-Cell Responses After SARS-CoV-2 Vaccination in PWH With Poor Immune Reconstitution.

Autor:	Benet S; Fundació Lluita contra les Infeccions, Infectious Diseases Department, Hospital Universitari Germans Trias I Pujol, Badalona, Spain., Blanch-Lombarte O; IrsiCaixa AIDS Research Institute, Hospital Germans Trias I Pujol, Badalona, Spain., Ainsua-Enrich E; IrsiCaixa AIDS Research Institute, Hospital Germans Trias I Pujol, Badalona, Spain., Pedreño-Lopez N; IrsiCaixa AIDS Research Institute, Hospital Germans Trias I Pujol, Badalona, Spain., Muñoz-Basagoiti J; IrsiCaixa AIDS Research Institute, Hospital Germans Trias I Pujol, Badalona, Spain., Raïch-Regué D; IrsiCaixa AIDS Research Institute, Hospital Germans Trias I Pujol, Badalona, Spain., Perez-Zsolt D; IrsiCaixa AIDS Research Institute, Hospital Germans Trias I Pujol, Badalona, Spain., Peña R; IrsiCaixa AIDS Research Institute, Hospital Germans Trias I Pujol, Badalona, Spain., Jiménez E; IrsiCaixa AIDS Research Institute, Hospital Germans Trias I Pujol, Badalona, Spain., Rodríguez de la Concepción ML; IrsiCaixa AIDS Research Institute, Hospital Germans Trias I Pujol, Badalona, Spain., Ávila C; IrsiCaixa AIDS Research Institute, Hospital Germans Trias I Pujol, Badalona, Spain., Cedeño S; IrsiCaixa AIDS Research Institute, Hospital Germans Trias I Pujol, Badalona, Spain., Escribà T; IrsiCaixa AIDS Research Institute, Hospital Germans Trias I Pujol, Badalona, Spain., Romero-Martín L; IrsiCaixa AIDS Research Institute, Hospital Germans Trias I Pujol, Badalona, Spain., Alarcón-Soto Y; Fundació Lluita contra les Infeccions, Infectious Diseases Department, Hospital Universitari Germans Trias I Pujol, Badalona, Spain., Rodriguez-Lozano GF; IrsiCaixa AIDS Research Institute, Hospital Germans Trias I Pujol, Badalona, Spain., Miranda C; Fundació Lluita contra les Infeccions, Infectious Diseases Department, Hospital Universitari Germans Trias I Pujol, Badalona, Spain., González S; Fundació Lluita contra les Infeccions, Infectious Diseases Department, Hospital Universitari Germans Trias I Pujol, Badalona, Spain., Bailón L; Fundació Lluita contra les Infeccions, Infectious Diseases Department, Hospital Universitari Germans Trias I Pujol, Badalona, Spain.; Autonomous University, Barcelona, Spain., Blanco J; IrsiCaixa AIDS Research Institute, Hospital Germans Trias I Pujol, Badalona, Spain.; Germans Trias i Pujol Research Institute, Badalona, Spain.; Faculty of Medicine, University of Vic-Central University of Catalonia , Vic, Spain.; CIBER Enfermedades Infecciosas, Instituto de Salud Carlos III, Madrid, Spain., Massanella M; IrsiCaixa AIDS Research Institute, Hospital Germans Trias I Pujol, Badalona, Spain.; CIBER Enfermedades Infecciosas, Instituto de Salud Carlos III, Madrid, Spain., Brander C; IrsiCaixa AIDS Research Institute, Hospital Germans Trias I Pujol, Badalona, Spain.; Faculty of Medicine, University of Vic-Central University of Catalonia , Vic, Spain.; CIBER Enfermedades Infecciosas, Instituto de Salud Carlos III, Madrid, Spain.; Catalan Institution for Research and Advanced Studies, Barcelona, Spain., Clotet B; Fundació Lluita contra les Infeccions, Infectious Diseases Department, Hospital Universitari Germans Trias I Pujol, Badalona, Spain.; IrsiCaixa AIDS Research Institute, Hospital Germans Trias I Pujol, Badalona, Spain.; Germans Trias i Pujol Research Institute, Badalona, Spain.; Faculty of Medicine, University of Vic-Central University of Catalonia , Vic, Spain., Paredes R; Fundació Lluita contra les Infeccions, Infectious Diseases Department, Hospital Universitari Germans Trias I Pujol, Badalona, Spain.; IrsiCaixa AIDS Research Institute, Hospital Germans Trias I Pujol, Badalona, Spain.; Germans Trias i Pujol Research Institute, Badalona, Spain.; Faculty of Medicine, University of Vic-Central University of Catalonia , Vic, Spain.; CIBER Enfermedades Infecciosas, Instituto de Salud Carlos III, Madrid, Spain., Esteve M; Preventive Medicine Service, Hospital Universitari Germans Trias I Pujol, Badalona, Spain.; Autonomous University, Barcelona, Spain., Izquierdo-Useros N; IrsiCaixa AIDS Research Institute, Hospital Germans Trias I Pujol, Badalona, Spain.; Germans Trias i Pujol Research Institute, Badalona, Spain.; CIBER Enfermedades Infecciosas, Instituto de Salud Carlos III, Madrid, Spain., Carrillo J; IrsiCaixa AIDS Research Institute, Hospital Germans Trias I Pujol, Badalona, Spain.; Germans Trias i Pujol Research Institute, Badalona, Spain.; CIBER Enfermedades Infecciosas, Instituto de Salud Carlos III, Madrid, Spain., Prado JG; IrsiCaixa AIDS Research Institute, Hospital Germans Trias I Pujol, Badalona, Spain.; Germans Trias i Pujol Research Institute, Badalona, Spain.; CIBER Enfermedades Infecciosas, Instituto de Salud Carlos III, Madrid, Spain., Moltó J; Fundació Lluita contra les Infeccions, Infectious Diseases Department, Hospital Universitari Germans Trias I Pujol, Badalona, Spain.; CIBER Enfermedades Infecciosas, Instituto de Salud Carlos III, Madrid, Spain., Mothe B; Fundació Lluita contra les Infeccions, Infectious Diseases Department, Hospital Universitari Germans Trias I Pujol, Badalona, Spain.; IrsiCaixa AIDS Research Institute, Hospital Germans Trias I Pujol, Badalona, Spain.; Faculty of Medicine, University of Vic-Central University of Catalonia , Vic, Spain.; CIBER Enfermedades Infecciosas, Instituto de Salud Carlos III, Madrid, Spain.
Jazyk:	angličtina
Zdroj:	The Journal of infectious diseases [J Infect Dis] 2022 Nov 28; Vol. 226 (11), pp. 1913-1923.
DOI:	10.1093/infdis/jiac406
Abstrakt:	Background: We analyzed humoral and cellular immune responses induced by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) messenger RNA (mRNA) vaccines in people with human immunodeficiency virus (HIV; PWH) who had CD4+ T-cell counts <200/µL (HIV<200 group). Methods: This prospective cohort study included 58 PWH in the HIV<200 group, 36 with CD4+ T-cell counts >500/µL (HIV>500 group), and 33 HIV-1-negative controls (control group). Antibodies against the SARS-CoV-2 spike protein (anti-S immunoglobulin [Ig] G) and the receptor-binding domain (anti-RBD IgG) were quantified before and 4 weeks after the first and the second doses of BNT162b2 or mRNA-1273 (at week 8). Viral neutralization activity and T-cell responses were also determined. Results: At week 8, anti-S/anti-RBD IgG responses increased in all groups (P < .001). Median (interquartile range) anti-S and anti-RBD IgG levels at week 8 were 153.6 (26.4-654.9) and 171.9 (61.8-425.8) binding antibody units (BAU)/mL, respectively, in the HIV<200 group, compared with 245.6 (145-824) and 555.8 (166.4-1751) BAU/mL in the HIV>500 group and 274.7 (193.7-680.4) and 281.6 (181-831.8) BAU/mL in controls (P < .05). Neutralizing capacity and specific T-cell immune responses were absent or reduced in 33% of those in the HIV<200 group, compared with 3.7% in the HIV>500 group (P < .01). Conclusions: One-third of PWH with CD4+ T-cell counts <200/µL show low anti-S/anti-RBD IgG levels, reduced in vitro neutralization activity against SARS-CoV-2, and no vaccine-induced T cells after receiving coronavirus disease 2019 mRNA vaccines. Competing Interests: Potential conflicts of interest. Unrelated to the submitted work, RP reports institutional grants from GileaD, MSD, VIIV, GSK, THERATECHNOLOGIES, LILLY. Unrelated to the submitted work, N.I-U. reports institutional grants from HIPRA, Pharma Mar, Grifols, Amassence and Palobiofarma. Unrelated to the submitted work, BM reports institutional grants from Janssen and Aelix Therapeutics. All other authors report no potential conflicts. All authors have submitted the ICMJE Form for Disclosure of Potential Conflicts of Interest. Conflicts that the editors consider relevant to the content of the manuscript have been disclosed. (© The Author(s) 2022. Published by Oxford University Press on behalf of Infectious Diseases Society of America. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu